Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 10/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15639563 | 0.99 | SMYD2 (0.41) | SMYD2METGRIN1GRIN2BASAH1 | |
| SCHEMBL15638983 | 0.95 | KMO (0.40) | SMYD2GRIN1GRIN2BKMO | |
| SCHEMBL15640138 | 0.93 | AR (0.45) | SMYD2AR | |
| SCHEMBL15639638 | 0.89 | ALDH1A1 (0.41) | — | |
| SCHEMBL15640030 | 0.89 | ASAH1 (0.41) | GRIN1GRIN2BASAH1KMOAR | |
| SCHEMBL16460372 | 0.87 | KMT2A (0.40) | GRIN1GRIN2BASAH1KMOAR | |
| SCHEMBL15639997 | 0.87 | L3MBTL1 (0.39) | GRIN1GRIN2BASAH1KMO | |
| SCHEMBL15639313 | 0.85 | KMT2A (0.38) | METGRIN1GRIN2BASAH1KMO | |
| SCHEMBL16459670 | 0.81 | KMO (0.43) | GRIN1GRIN2BKMO | |
| SCHEMBL15637974 | 0.80 | SMYD2 (0.44) | SMYD2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR2, ACVR1, TGFBR1 | SMYD2 2412/4885MET 38/4885GRIN1 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.